Phenibut is sold as a supplement but has a high potential for abuse and dependency. Access this toolkit focused on mechanism of misuse, clinical presentation, and management of acute intoxication and withdrawal among other timely topics.
Searching for Solutions
Sold as a readily available supplement, phenibut is not approved for medical use in the U.S. It has a high potential for abuse and dependency making AAPP’s newest toolkit an important read. Author Sarah Thomason addresses phenibut’s mechanism of misuse, clinical presentation, and management of acute intoxication and withdrawal among other topics. Check out this timely member resource today.
Eliminate confusion about the use of buprenorphine and methadone in acute care settings by accessing an FAQ resource addressing the most common questions and scenarios.
Despite their importance as first-line options for OUD treatment, confusion remains regarding their use in acute care settings, especially when patients seek care at institutions that do not have opioid treatment program (OTP) licensure. AAPP members and authors Zoe Karovolis, Emily Leppien, and Annette Percy have developed a go-to resource addressing frequently asked questions regarding the use of buprenorphine and methadone in acute care settings.
These findings suggest that glucagon-like peptide-1 receptor agonist monotherapy may alter some nicotine outcomes in people who smoke, irrespective of cessation treatment.
GLP-1 RA use in adults on methadone with both OUD and T2D was associated with lower rates of cardiometabolic and mental health complications.
Findings suggest brief educational interventions can help primary care providers recognize misinformation that may otherwise undermine implementation efforts.
This study conducted a systematic review following PRISMA 2020 guidelines.
Alleviate confusion about the use of buprenorphine and methadone in acute care settings through AAPP’s toolkit.
Authored by AAPP members Zoe Karavolis, Emily Leppien and Annette Percy, AAPP has released an FAQ to help clinicians address frequently asked questions regarding the use of buprenorphine and methadone in acute care settings.
SAMHSA Resource - Healthy Starts: Postpartum OUD Care Transitions for Mother and Infant (Case Study)
This publication highlights best practices for managing OUD during and after pregnancy and summarizes current evidence on treating perinatal substance use disorder.
Nearly 1 in 5 adolescents and young adults are turning to AI chatbots for advice when they’re sad, angry, nervous or stressed, according to a new study. The findings, from the research institute RAND, represent an increase from early 2025, when the nonprofit conducted a similar survey. At the time, around 13% of respondents said they used chatbots for such advice, but the share rose to 19% in the group’s latest survey in November.
This report used literature review and data analysis to gain insight into existing research and the real-world impact by examining Medicare fee-for-service and Part D data from 2021 to 2023.
These findings emphasize the need for targeted, system-level strategies to improve access, adherence, and coordinated care for individuals with schizophrenia within Medicaid programs.
This session reviews practical, evidence-based approaches for bringing overdose prevention and opioid use disorder (OUD) treatment into pediatric primary care. It will cover screening and risk assessment, brief counseling to reduce the consequences of drug use, naloxone distribution, and pathways for initiating and managing medications for OUD (including buprenorphine).
This webinar will detail the benefits of SBIRT, the appropriate screening tools to use and how to use these to facilitate change-focused conversations.
The FDA granted de novo approval for a neuromodulation device to treat symptoms associated with post-traumatic stress disorder (PTSD). The wearable, non-invasive device -- dubbed Modius Spero -- uses electrical vestibular system stimulation to target specific brain areas. It is prescribed and overseen by a healthcare professional as part of a comprehensive PTSD care plan.
The Department of Veterans Affairs (VA) on Tuesday announced a new clinical trial of methylenedioxymethamphetamine-assisted therapy, more commonly known as MDMA, to evaluate the safety and efficacy when treating current and former military personnel for severe mental health disorders including posttraumatic stress disorder (PTSD) and alcohol use disorder.
The SSP-based model provided rapid access to buprenorphine prescriptions, but precipitated withdrawal was a common complication.
Public sentiment on Regulations.gov supports the United States Drug Enforcement Administration's proposal for cannabis rescheduling, though the majority views the proposed Schedule III classification as inadequate and supports further rescheduling or complete de-scheduling of cannabis.
This study offers novel data on opioid-related medication access for adolescents with illicit fentanyl exposure.
Formalizing FA assessment and diagnosis, and improving reimbursement mechanisms, may reduce potential health inequities between market-driven and publicly funded SUD treatment centers in FA treatment and referral resources.
This study's findings suggest that provision of in-jail MOUD could improve methadone uptake in the community.
Social anxiety and psychiatric concerns are salient barriers to attending a variety of MHG groups and to MHG involvement.
This randomized controlled trial provides the first evidence that a pharmacological intervention, buprenorphine, significantly sustains and enhances the antisuicidal effects of ketamine in MDD.